Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

被引：0
|
作者：
Peters, Anthea [1 ]
Nowakowski, Grzegorz S. [2 ]
Dabas, Rosy [3 ]
Amoloja, Theresa [4 ]
Xue, Zhenyi [4 ]
Koch, Caroline [3 ]
Waltl, Eva E. [5 ]
Fleury, Isabelle [6 ]
机构：
[1] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[2] Mayo Clin, Div Hematol, Dept Med, Rochester, MN USA
[3] Incyte Biosci Canada, Pointe Claire, PQ, Canada
[4] Incyte Corp, Wilmington, DE USA
[5] MorphoSys AG, Planegg, Germany
[6] Univ Montreal, Maisonneuve Rosemt Hosp, Montreal, PQ, Canada
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158550
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3811 / 3813
页数：3
相关论文
共 50 条
  • [1] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    [J]. BLOOD, 2023, 142
  • [3] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    [J]. BLOOD, 2022, 140 : 7906 - 7907
  • [4] A comparison of sampling methods to select real-world relapsed/refractory (R/R) diffuse large-cell B-cell lymphoma (DLBCL) patients with multiple eligible index dates
    Dillon, Paul
    Surinach, Andy
    Castro, Felipe
    Spielewoy, Nathalie
    Black, James A.
    Shang, Aijing
    Radford, John
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 430 - 430
  • [5] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Maakaron, Joseph
    Asch, Adam S.
    Popplewell, Leslie L.
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colin
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    O'Hear, Carol
    Ren, Xuehan
    Villa, Bertha
    Lal, Indu
    Smith, Sonali M.
    Advani, Ranjana H.
    [J]. BLOOD, 2022, 140 : 3728 - 3730
  • [6] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    Van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles Andre
    Maziarz, Richard Thomas
    Anak, Oezlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    [J]. BLOOD, 2017, 130
  • [7] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [8] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
    Bell, Jill A.
    Cherepanov, Dasha
    Revicki, Dennis
    Speck, Rebecca M.
    Swett, Laura
    Stumpo, Kate
    Rong, Yuanxin
    Gordon, Leo I.
    [J]. QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
  • [9] Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
    Atesoglu, Elif Birtas
    Gulbas, Zafer
    Uzay, Ant
    Ozcan, Muhit
    Ozkalemkas, Fahir
    Dal, Mehmet Sinan
    Kalyon, Hakan
    Akay, Olga Meltem
    Deveci, Burak
    Bekoz, Huseyin
    Sevindik, Omur Gokmen
    Toptas, Tayfur
    Yilmaz, Fergun
    Koyun, Derya
    Alkis, Nihan
    Alacacioglu, Inci
    Sonmez, Mehmet
    Yavasoglu, Irfan
    Tombak, Anil
    Mehtap, Ozgur
    Kurnaz, Fatih
    Yuce, Orhan Kemal
    Karakus, Volkan
    Turgut, Mehmet
    Kurekci, Derya Deniz
    Ayer, Mesut
    Keklik, Muzaffer
    Buyuktas, Deram
    Ozbalak, Murat
    Ferhanoglu, Burhan
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 663 - 673
  • [10] CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): A 'Real-World' Analysis of Patterns of Failure and Role of Bridging Therapy
    Ravella, Revathi
    Zhang-Velten, Elizabeth Ren
    Awan, Farrukh T.
    Rizvi, Syed M.
    Shah, Jennifer L.
    Desai, Neil B.
    Geethakumari, Praveen Ramakrishnan
    Kumar, Kiran A.
    [J]. BLOOD, 2020, 136
12345